Biotech confidence surges in 2026 as China leads growth and deal activity spikes

Industry observers noted a marked shift in tone at two major 2026 biotech gatherings – the DIA China meeting in Shanghai and the BIO International Convention in San Diego – where participants expressed optimism about the sector’s outlook.

Deal data for the first quarter of the year showed the highest number of agreements since 2023, roughly twice the volume recorded in the same period a year earlier, as large pharmaceutical firms seek to broaden their pipelines ahead of the 2030 patent cliff.

China stood out as a growth engine, with officials highlighting the country’s long‑term planning, skilled workforce and strong infrastructure. A deputy mayor at the DIA event outlined the "three Fs" strategy – being first in China, first in humans and first in class – that many biotech companies are now aiming to achieve.